Ninety-eight semesters of cytochrome P450 enzymes and related topics—What have I taught and learned?

“

TL;DR

This is a personal reflection by F. Peter Guengerich on his 50+ year career studying cytochrome P450 enzymes, from his upbringing on a farm to his role as a leading biochemist. The article highlights his contributions to understanding P450 structure, function, and roles in drug metabolism and toxicology, as well as his extensive mentoring of over 170 trainees. The clinical significance lies in the foundational knowledge of P450s that underpins modern drug development, personalized medicine, and the prediction of drug-drug interactions.

Full summary

3,443 CHARS

**Background:** This article is a personal reflection by F. Peter Guengerich, a prominent biochemist, detailing his career spanning 98 semesters as a faculty member at Vanderbilt University. The narrative covers his early life on a farm in Illinois, his education at the University of Illinois, graduate studies at Vanderbilt under Harry Broquist, postdoctoral work with Minor J. Coon at the University of Michigan, and his subsequent independent career at Vanderbilt. The central theme is his lifelong research on cytochrome P450 (P450) enzymes, which are critical for the metabolism of drugs, toxins, and endogenous compounds. Guengerich emphasizes the importance of mentorship, hard work, and perseverance in scientific research.

**Methods:** The article is a narrative review and personal reflection, not a systematic study. Guengerich describes his research trajectory, including key experimental approaches used in his lab over decades. These include protein purification from tissues (e.g., human liver), development of quantitative immunoblotting (Western blotting) for P450 quantification, heterologous expression of human P450s in *Escherichia coli*, stopped-flow spectrophotometry, rapid-quench kinetic analysis, mass spectrometry (including LC-MS), X-ray crystallography (in collaboration with Martin Egli), and metabolomic approaches to identify substrates for orphan P450s. He also discusses his roles as a mentor, editor (including Associate Editor and interim Editor-in-Chief of the *Journal of Biological Chemistry*), and director of the Vanderbilt Center in Molecular Toxicology.

**Key Results:** Guengerich's lab made numerous seminal contributions. They purified and characterized multiple rat and human P450s, including P450 3A4 (originally termed P450 NF), which metabolizes approximately half of all marketed drugs. They developed the first quantitative immunoblotting method for P450s. They elucidated the roles of specific P450s in drug metabolism, carcinogen activation, and steroidogenesis. Key mechanistic findings include the demonstration that P450s can catalyze oxidations via single electron transfer and the characterization of reaction processivity for steroidogenic P450s (e.g., P450 17A1, 19A1, 51A1). They identified the function of the orphan P450 27C1 as a retinoid 3,4-desaturase, highly expressed in human skin. The lab also made contributions to understanding DNA adduct formation and DNA polymerase misincorporation. Guengerich notes that his most highly cited paper (≥3500 Google citations) is on immunochemical quantification of human P450s, while some detailed mechanistic studies were less cited.

**Clinical Implications:** The research has profound clinical implications. Understanding which P450 enzymes metabolize specific drugs allows prediction of drug-drug interactions, inter-individual variability in drug response (pharmacogenetics), and adverse reactions. For example, work on terfenadine and P450 3A4 helped explain serious, sometimes fatal, drug interactions, leading to changes in FDA regulations. The characterization of P450s involved in steroidogenesis (e.g., P450 17A1, 19A1) has implications for endocrine disorders and cancer therapy. The discovery of P450 27C1's role in retinoid metabolism in skin may have implications for dermatology and vision science. Overall, Guengerich's work provides the biochemical foundation for personalized medicine and safer drug development.